Navigation Links
AACR announces new journal, Cancer Discovery
Date:10/29/2010

PHILADELPHIA The American Association for Cancer Research announces the launch of its newest journal, Cancer Discovery, which will publish high-impact, peer-reviewed articles describing major advances in basic and clinical research. Its unique format will feature game-changing research, review articles, perspectives and commentaries, news, and "Research Watch" summaries of important journal articles. Cancer Discovery is a new addition to the AACR's robust publication program.

Cancer Discovery combines the expertise and experience of founding Editors-in-Chief Lewis C. Cantley, Ph.D., and Jos Baselga, M.D., Ph.D., along with full-time professional editors. Mark W. Landis, Ph.D., has been appointed executive editor.

"Cancer Discovery will make major contributions to the growing body of knowledge and be a touchstone for the diverse professional community in the cancer field," said Cantley.

Baselga added, "Topics will span the spectrum of cancer science and medicine; from the laboratory to the clinic to epidemiologic and prevention studies. This is a vital resource for everyone working on the problem of cancer."

"Facilitating communication and cross-disciplinary interactions in the field by publishing excellent journals is a core mission of the American Association for Cancer Research," said AACR Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.). "We are thrilled that Cancer Discovery will provide a new publication outlet that captures the most significant work in the field and inspires thinking that will accelerate the pace of breakthroughs."

Cantley is director of the cancer center and chief of the division of signal transduction at Beth Israel Deaconess Medical Center. He is also professor of systems biology at Harvard Medical School. Cantley's laboratory discovered PI3 Kinase (PI3K) and revealed its role in a pathway that controls cell growth and cell transformation. PI3K is implicated in many cancers as well as in other diseases. As a result, pharmaceutical intervention in the PI3K pathway is being explored.

Baselga is chief of the division of hematology/oncology and associate director of the Massachusetts General Hospital Cancer Center. He is also professor of medicine at Harvard Medical School. Baselga's research focuses on the clinical development of novel, molecular-targeted agents for the therapy of cancer, particularly breast cancer. He conducted the initial clinical trials with the monoclonal antibodies cetuximab and trastuzumab and has been involved in the clinical development of several new agents including pertuzumab and PI3K inhibitors. His main focus in the laboratory and clinic is in the area of novel anti-HER2 agents, in the identification of mechanisms of resistance to anti-HER2 agents.

Landis was previously with Cell Press, most recently as senior editor for the journal Molecular Cell. Landis holds a doctorate in biological chemistry and molecular pharmacology from Harvard University, where his work focused on breast cancer. He has held research and teaching assistantships at Dartmouth College, the University of Massachusetts Medical School and Children's Hospital in Boston.


'/>"/>

Contact: Michele Sharp
michele.sharp@aacr.org
267-646-0622
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand
2. ClinOps Announces Appointment of New President and CEO
3. Aware, Inc. Announces Q310 Earnings Conference Call
4. NYSCF announces 2010 NYSCF Investigators
5. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
6. Penn Vet announces $100,000 winners of 2010 World Leadership Award and Student Inspiration Awards
7. TERMIS-North America announces speakers for annual event
8. American Society of Agronomy announces the class of 2010 Fellows
9. American Society of Agronomy announces award recipients
10. Biophysical Society announces 2011 society fellows
11. ActiveCare, Inc. Announces Capital Raise Commitment and Balance Sheet Restructuring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... May 23, 2017 , ... ... for research and the development of cardiac regeneration therapies. The development of ... of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further enrichment of CM ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Vortex Biosciences ... “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology ” in ... of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig at the ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Cambridge Semantics ... splash at this year’s Bio-IT World Conference and Expo in Boston May ... Lake® 4.0 solution. The Anzo Smart Data Lake is also a finalist for ...
(Date:5/22/2017)... PA (PRWEB) , ... May 22, 2017 , ... ... announced today that it is exhibiting in booth B2 at the Association for ... Pittsburgh, May 22-25. , In addition to demonstrating its Cancer Diagnostic Cockpit ...
Breaking Biology Technology: